The FE65 proteins and Alzheimer's disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The FE65s (FE65, FE65L1, and FE65L2) are a family of multidomain adaptor proteins that form multiprotein complexes with a range of functions. FE65 is brain‐enriched, whereas FE65L1 and FE65L2 are more widely expressed. All three members contain a WW domain and two PTB domains. Through the PTB2 domain, they all interact with the Alzheimer's disease amyloid precursor protein (APP) intracellular domain (AICD) and can alter APP processing. After sequential proteolytic processing of membrane‐bound APP and release of AICD to the cytoplasm, FE65 can translocate to the nucleus to participate in gene transcription events. This role is further mediated by interactions of FE65 PTB1 with the transcription factors CP2/LSF/LBP1 and Tip60 and the WW domain with the nucleosome assembly factor SET. However, FE65 target genes have not yet been confirmed. The FE65 PTB1 domain also interacts with two cell surface lipoproteins receptors, the low‐density lipoprotein receptor‐related protein (LRP) and ApoEr2, forming trimeric complexes with APP. The FE55 WW domain also binds to mena, through which it functions in regulation of the actin cytoskeleton, cell motility, and neuronal growth cone formation. While single knockout mice appear normal, double FE65−/−/FE65L1−/− mice have substantial neurodevelopmental defects. These include heterotopic neurons and axonal pathfinding defects, findings similar to findings in both Mena and triple APP:APLP1:APLP2 knockout mice and also lissencephalopathies in humans. Thus APPs, FE65s, and mena may act together in a developmental signalling pathway. This article reviews the known functions of the FE65 family and their role in APP function and Alzheimer's disease. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Notch signalling: a simple pathway becomes complex
Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Reelin, lipoprotein receptors and synaptic plasticity
Herz, J., & Chen, Y. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn2009 · Cited by 524
Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Fiore, F., Zambrano, N., Minopoli, G., Donini, V., Duilio, A., & Russo, T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.30853 · Cited by 294 · cited 4×
“The three FE65s all bind to the Alzheimer’s disease (AD) amyloid precursor protein (APP; Fiore et al., 1995; McLoughlin and Miller, 1996; Bressler et al., 1996; Borg et al., 1996; Guénette et al., 1996; Duilio et al., 1998; Tanahashi and Tabira, 1999b).”
BackgroundInfluentialSabo, S. L., Ikin, A. F., Buxbaum, J. D., & Greengard, P. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.7.1403 · Cited by 237 · cited 1×
“Together, APP and FE65 have been implicated in the regulation of actin-based cell motility and have been found to colocalize in neuronal growth cones and interact in synaptic terminals, suggesting potential roles for APP/FE65/Mena in synaptic plasticity (Sabo et al., 2001, 2003).”
BackgroundSabo, S. L., Ikin, A. F., Buxbaum, J. D., & Greengard, P. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05407.2003 · Cited by 187 · cited 1×
“Together, APP and FE65 have been implicated in the regulation of actin-based cell motility and have been found to colocalize in neuronal growth cones and interact in synaptic terminals, suggesting potential roles for APP/FE65/Mena in synaptic plasticity (Sabo et al., 2001, 2003).”
BackgroundFE65 interaction with the ApoE receptor ApoEr2
Hoe, H.-S., Magill, L. A., Guenette, S., Fu, Z., Vicini, S., & Rebeck, G. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600728200 · Cited by 69
Cited by
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
“When heterozygous X11 or Fe65 knockout mice are crossed with APP overexpressing mice, brain Aβ accumulation increases significantly (Saluja et al. 2009); moreover, mice that overexpress X11 or Fe65 have diminished brain Aβ accumulation (Lee et al. 2003, McLoughlin & Miller 2008).”
BackgroundThe multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes
Nhan, H. S., Chiang, K., & Koo, E. H. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1347-2 · Cited by 256
Wang, Q., Li, W.-X., Dai, S.-X., Guo, Y.-C., Han, F.-F., Zheng, J.-J., Li, G.-H., & Huang, J.-F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161032 · Cited by 88
Bukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 88
Matatall, K. A., Wathan, T. K., Nguyen, M., Chen, H., McDonald, A., Qi, G., Belk, J. A., Florez, M. A., Le, D. T., Olarinde, T., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.06.006 · Cited by 23
Metadata
- Authors
- McLoughlin, D. M., & Miller, C. C. J.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2007-09-07
- Volume
- 86
- Issue
- 4
- Pages
- 744-754
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W1975821930
- Cited by
- 138
- References
- 8
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FE65 proteins and Alzheimer's disease. https://app.cochat.ai/papers/10.1002/jnr.21532
- The paper
- McLoughlin, D. M., & Miller, C. C. J. (2008). The FE65 proteins and Alzheimer's disease. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.21532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.